Alembic Pharma's consolidated profit rose 21% to Rs 185 crore in Q2 FY26, led by strong performance in US generics, APIs, and ...

Alembic Pharmaceuticals reported a strong second quarter with profit rising 21% year-on-year to ₹185 crore, supported by ...

N-CAPIE offers a faster way to create and continuously optimise API implementations, says Sam Selmer-Olsen, MD at Bateleur Software.

How Can Robust NHI Management Transform Your Cybersecurity Strategy? How non-human identities (NHI) can strengthen your organization’s cybersecurity framework? Efficiently managing NHIs is pivotal for ...

Alembic Pharmaceuticals rallied 3.87% to Rs 960.10 after the company's consolidated net profit jumped 20.40% to Rs 184.71 crore in Q2 FY26, compared to Rs 153.41 crore posted in Q2 FY25.

Greg Miraglia and Jeff Nardinelli of Quinn Emanuel Urquhart & Sullivan LLP discuss the potential and successes of low-orbit ...

Licensing Revenue: The Company recognized approximately USD 1.28 million in licensing revenue for Q3 2025, compared to USD 0.39 million for the same period in 2024, an increase of approximately 230% ...

Investors will watch for management commentary on the US recovery outlook, particularly around the uptake of Lanreotide and ...

Abbvie (($ABBV)) has held its Q3 earnings call. Read on for the main highlights of the call. AbbVie’s latest earnings call ...

The next decade’s defining competition isn’t about who builds the best AI, but who learns fastest — pitting U.S. frontier research against China.

Our Bureau, New Delhi Friday, October 31, 2025, 14:15 Hrs [IST] Cipla Ltd has reported a growth of 3.7% in net profit for the quarter ...

Cipla Ltd (BOM:500087) reports an all-time high quarterly revenue, strategic biosimilar launch in the US, and revised EBITDA guidance amidst market challenges.